IMF Publication - Understanding Tecvayli™
IMF Publication - Understanding Tecvayli™
Regular price
$0.00 USD
Regular price
Sale price
$0.00 USD
Unit price
per
Tecvayli™ (teclistmab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma. Tecvayli is indicated for patients with relapsed or refractory myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli is an immunotherapy, a treatment that enhances the patient’s own immune system to attack their myeloma cells.
Materials
Materials
Shipping & Returns
Shipping & Returns
Dimensions
Dimensions
Care Instructions
Care Instructions
Image with text
Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.
-
Free Shipping
Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.
-
Hassle-Free Exchanges
Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.